Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection

Stuart Dowall, Jo Callan, Antra Zeltina, Ibrahim Al-Abdulla, Thomas Strecker, Sarah K. Fehling, Verena Krähling, Andrew Bosworth, Emma Rayner, Irene Taylor, Sue Charlton, John Landon, Ian Cameron, Roger Hewson, Abdulsalami Nasidi, Thomas A. Bowden, Miles Carroll*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)


The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host response. Recombinant EBOV-GP ectodomain (EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and elicited a robust immune response and produced high titers of high avidity polyclonal antibodies. Investigation of the neutralizing activity of the ovine antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used for an in vivo Guinea pig study. When EBOTAb was delivered 6 hours after challenge, all animals survived without experiencing fever or other clinical manifestations. In a second series of Guinea pig studies, the administration of EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100% and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb in protecting against EBOV-induced disease.

Original languageEnglish
Pages (from-to)1124-1133
Number of pages10
JournalJournal of Infectious Diseases
Issue number7
Publication statusPublished - 1 Apr 2016

Bibliographical note

Publisher Copyright:
© The Author 2015.


  • Antibody
  • Ebola
  • Efficacy
  • Neutralization
  • Therapeutic


Dive into the research topics of 'Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection'. Together they form a unique fingerprint.

Cite this